
|Videos|November 18, 2021
A urologist gives his take on PSMA in prostate cancer
Author(s)Urology Times staff
“[Out] of everything going on, this is probably 1 of the most exciting areas in prostate cancer,” says Jason M. Hafron, MD.
Advertisement
In this video, Jason M. Hafron, MD, shares why he thinks PSMA is “disruptive technology” in prostate cancer. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of urology at the William Beaumont School of Medicine, Oakland University; and the director of robotic surgery at Beaumont Hospital Royal Oak in Michigan. He was speaking at the 2021 LUGPA annual meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Experts discuss the challenge of detecting CIS in bladder cancer
2
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
3
FDA grants tentative approval to generic olaparib tablets across previously approved indications
4
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
5












